COVID-19 Therapeutic Trials: Investigators Should Join Forces Rather Than Conduct Single Site Studies
Executive Summary
‘Treacherous combination’ of small clinical trials, lagging enrollment, unreported results and uncompleted trials is hindering COVID-19 research, former FDA Commissioner Califf says. Yale professor calls for a ‘Manhattan Project’ around knowledge and a change in the academic star system.
You may also be interested in...
Operation Warp Speed Had Trouble Enrolling Patients In COVID-19 Therapeutic Research
US FDA Acting Commissioner Woodcock says there is ‘a long list’ of lessons learned in the OWS therapeutics group, noting trial bureaucracy and the lack of resources and support for community centers.
Early ‘Scattershot’ Approach To COVID-19 Therapeutic Research Generated Little Actionable Data
US FDA and NIH leaders cite lack of early clinical trial coordination as a weakness in the pandemic response that led to use of compounds that were potentially harmful and, even today, still not proven to be effective.
Dexamethasone COVID-19 Findings Leave Authorities Bracing for Yet Another Demand Surge
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.